IRIS Accounts Production v25.1.4.42 07034936 Board of Directors 1.1.24 31.12.24 31.12.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh070349362023-12-31070349362024-12-31070349362024-01-012024-12-31070349362022-12-31070349362023-01-012023-12-31070349362023-12-3107034936ns15:EnglandWales2024-01-012024-12-3107034936ns14:PoundSterling2024-01-012024-12-3107034936ns10:Director12024-01-012024-12-3107034936ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3107034936ns10:SmallEntities2024-01-012024-12-3107034936ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3107034936ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3107034936ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3107034936ns10:FullAccounts2024-01-012024-12-310703493612024-01-012024-12-3107034936ns10:Director22024-01-012024-12-3107034936ns10:Director32024-01-012024-12-3107034936ns10:RegisteredOffice2024-01-012024-12-3107034936ns5:CurrentFinancialInstruments2024-12-3107034936ns5:CurrentFinancialInstruments2023-12-3107034936ns5:ShareCapital2024-12-3107034936ns5:ShareCapital2023-12-3107034936ns5:RetainedEarningsAccumulatedLosses2024-12-3107034936ns5:RetainedEarningsAccumulatedLosses2023-12-3107034936ns5:NetGoodwill2024-01-012024-12-3107034936ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3107034936ns5:LandBuildings2024-01-012024-12-3107034936ns5:PlantMachinery2024-01-012024-12-3107034936ns5:NetGoodwill2023-12-3107034936ns5:NetGoodwill2024-12-3107034936ns5:NetGoodwill2023-12-3107034936ns5:LandBuildings2023-12-3107034936ns5:PlantMachinery2023-12-3107034936ns5:LandBuildings2024-12-3107034936ns5:PlantMachinery2024-12-3107034936ns5:LandBuildings2023-12-3107034936ns5:PlantMachinery2023-12-3107034936ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3107034936ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3107034936ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-12-3107034936ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2023-12-31
REGISTERED NUMBER: 07034936 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2024

for

Dv-pharm Limited

Dv-pharm Limited (Registered number: 07034936)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


Dv-pharm Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: Mr Dipak Vanechand Mehta
Mrs Nileema Dipak Mehta
Mr Anish Dipak Mehta





REGISTERED OFFICE: Devonshire House
582 Honeypot Lane
Stanmore
MIDDLESEX
HA7 1JS





REGISTERED NUMBER: 07034936 (England and Wales)

Dv-pharm Limited (Registered number: 07034936)

Statement of Financial Position
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 23,776 28,531
Tangible assets 5 11,146 12,127
34,922 40,658

CURRENT ASSETS
Stocks 85,250 84,591
Debtors 6 380,690 377,517
Prepayments and accrued income 48,240 50,014
Cash at bank and in hand 177,369 122,363
691,549 634,485
CREDITORS
Amounts falling due within one year 7 201,866 112,331
NET CURRENT ASSETS 489,683 522,154
TOTAL ASSETS LESS CURRENT
LIABILITIES

524,605

562,812

PROVISIONS FOR LIABILITIES 2,118 2,304
NET ASSETS 522,487 560,508

CAPITAL AND RESERVES
Called up share capital 521,624 521,624
Retained earnings 863 38,884
SHAREHOLDERS' FUNDS 522,487 560,508

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Dv-pharm Limited (Registered number: 07034936)

Statement of Financial Position - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 August 2025 and were signed on its behalf by:





Mr Dipak Vanechand Mehta - Director


Dv-pharm Limited (Registered number: 07034936)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Dv-pharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2010, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land and buildings - in accordance with the property
Plant and machinery etc - 15% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Dv-pharm Limited (Registered number: 07034936)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 11 (2023 - 10 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 January 2024
and 31 December 2024 95,110
AMORTISATION
At 1 January 2024 66,579
Charge for year 4,755
At 31 December 2024 71,334
NET BOOK VALUE
At 31 December 2024 23,776
At 31 December 2023 28,531

5. TANGIBLE FIXED ASSETS
Plant and
Land and machinery
buildings etc Totals
£    £    £   
COST
At 1 January 2024 9,702 51,407 61,109
Additions - 1,010 1,010
At 31 December 2024 9,702 52,417 62,119
DEPRECIATION
At 1 January 2024 6,240 42,742 48,982
Charge for year 577 1,414 1,991
At 31 December 2024 6,817 44,156 50,973
NET BOOK VALUE
At 31 December 2024 2,885 8,261 11,146
At 31 December 2023 3,462 8,665 12,127

6. DEBTORS
31.12.24 31.12.23
£    £   
Amounts falling due within one year:
Other debtors 366,327 363,154

Amounts falling due after more than one year:
Other debtors 14,363 14,363

Aggregate amounts 380,690 377,517

Dv-pharm Limited (Registered number: 07034936)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade creditors 107,965 83,916
Taxation and social security 28,694 28,081
Other creditors 65,207 334
201,866 112,331

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

As at 31 December 2024, DV-Pharm Ltd owed £36,140 to its directors. This amount is reflected accordingly in their respective director`s loan account in credit balances, which is shown under Creditors due within one year. Please be advised that both the directors have agreed to provide this loan on an interest free basis and the loan is payable on demand.

9. RELATED PARTY DISCLOSURES

During the year ended 31 December 2024, DV-Pharm Ltd provided a short-term loan of £345,000 to a related company on an interest free basis and the loan is repayable on demand. This loan amount is shown as Other Debtors under Debtors due within one year.

10. ULTIMATE CONTROLLING PARTY

The controlling party is Mr Dipak Vanechand Mehta.

The ultimate controlling party is Mr Dipak Vanechand Mehta.